Agios Pharmaceuticals Future Growth
Future criteria checks 2/6
Agios Pharmaceuticals is forecast to grow earnings and revenue by 29.4% and 45.1% per annum respectively. EPS is expected to grow by 32.8% per annum. Return on equity is forecast to be -26.5% in 3 years.
Key information
29.4%
Earnings growth rate
32.8%
EPS growth rate
Biotechs earnings growth | 0% |
Revenue growth rate | 45.1% |
Future return on equity | -26.5% |
Analyst coverage | Good |
Last updated | 23 Feb 2024 |
Recent future growth updates
Recent updates
Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2026 | 199 | -300 | -234 | N/A | 8 |
12/31/2025 | 115 | -360 | -247 | -277 | 9 |
12/31/2024 | 64 | -317 | -336 | -98 | 9 |
12/31/2023 | 27 | -352 | -315 | -296 | N/A |
9/30/2023 | 24 | -220 | -308 | -290 | N/A |
6/30/2023 | 20 | -210 | -300 | -299 | N/A |
3/31/2023 | 19 | -218 | -309 | -307 | N/A |
12/31/2022 | 14 | -232 | -314 | -309 | N/A |
9/30/2022 | 10 | -367 | -337 | -327 | N/A |
6/30/2022 | 6 | -369 | -350 | -341 | N/A |
3/31/2022 | 1 | -360 | -392 | -384 | N/A |
12/31/2021 | N/A | -357 | -413 | -407 | N/A |
9/30/2021 | N/A | -342 | -374 | -373 | N/A |
6/30/2021 | N/A | -337 | -363 | -356 | N/A |
3/31/2021 | N/A | -336 | -317 | -306 | N/A |
12/31/2020 | N/A | -329 | -305 | -291 | N/A |
9/30/2020 | 35 | -347 | -355 | -335 | N/A |
6/30/2020 | 61 | -374 | -370 | -352 | N/A |
3/31/2020 | 88 | -402 | -387 | -373 | N/A |
12/31/2019 | N/A | -301 | -383 | -371 | N/A |
9/30/2019 | 112 | -401 | -358 | -351 | N/A |
6/30/2019 | 102 | -389 | -337 | -329 | N/A |
3/31/2019 | 116 | -348 | -316 | -309 | N/A |
12/31/2018 | 94 | -346 | -311 | -304 | N/A |
9/30/2018 | 74 | -343 | -312 | -305 | N/A |
6/30/2018 | 70 | -325 | -325 | -319 | N/A |
3/31/2018 | 41 | -339 | -316 | -310 | N/A |
12/31/2017 | 43 | -315 | -290 | -285 | N/A |
9/30/2017 | 56 | -283 | N/A | -262 | N/A |
6/30/2017 | 53 | -269 | N/A | -233 | N/A |
3/31/2017 | 49 | -241 | N/A | -17 | N/A |
12/31/2016 | 70 | -198 | N/A | 39 | N/A |
9/30/2016 | 53 | -183 | N/A | 59 | N/A |
6/30/2016 | 50 | -160 | N/A | 83 | N/A |
3/31/2016 | 56 | -136 | N/A | -70 | N/A |
12/31/2015 | 59 | -118 | N/A | -77 | N/A |
9/30/2015 | 68 | -104 | N/A | -54 | N/A |
6/30/2015 | 96 | -60 | N/A | -53 | N/A |
3/31/2015 | 91 | -46 | N/A | -58 | N/A |
12/31/2014 | 65 | -54 | N/A | -59 | N/A |
9/30/2014 | 57 | -39 | N/A | -65 | N/A |
6/30/2014 | 30 | -55 | N/A | -57 | N/A |
3/31/2014 | 28 | -47 | N/A | -71 | N/A |
12/31/2013 | 26 | -44 | N/A | -56 | N/A |
9/30/2013 | 25 | -49 | N/A | -54 | N/A |
6/30/2013 | 25 | -40 | N/A | -51 | N/A |
3/31/2013 | 25 | -30 | N/A | -46 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: AGIO * is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: AGIO * is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: AGIO * is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: AGIO *'s revenue (45.1% per year) is forecast to grow faster than the MX market (6.8% per year).
High Growth Revenue: AGIO *'s revenue (45.1% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: AGIO * is forecast to be unprofitable in 3 years.